Furthermore, citrulline plasma concentrations are suggested for use as a prognostic marker for parenteral nutrition weaning (if citrullinemia is >20 micromol/L) [47], and increased plasma concentrations of citrulline were observed in SBS patients when treated with the GLP-2 analog teduglutide [21]. This evidence concerns the gene GCG and citrullinemia type I.